| Martin, Claudio |
| Completed | 2 | 18 | Canada | recombinant human annexin A5, SY-005, Placebo | Lawson Health Research Institute, Ontario Ministry of Colleges and Universities, London Health Sciences Foundation | Coronavirus Infection, Sepsis | 04/22 | 12/22 | | |
| Completed | N/A | 3622 | Europe, Canada, US, RoW | 7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment. | Sunnybrook Health Sciences Centre | Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial | 05/23 | 08/23 | | |
PROMIZING, NCT02447692: Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The Study |
|
|
| Completed | N/A | 575 | Europe, Canada, RoW | PSV ventilation strategy, PAV+ ventilation strategy | Lawson Health Research Institute, Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group | Critically Ill, Acute Respiratory Failure | 07/24 | 07/24 | | |
| Izawa, Jonathan |
| Active, not recruiting | 3 | 408 | Canada | Metformin, Metformin hydrochloride, Placebo, Placebo tablet | University Health Network, Toronto | Prostate Cancer | 02/24 | 08/24 | | |
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients |
|
|
| Recruiting | 2 | 125 | Canada, US | Ruvidar® (TLD-1433) Bladder infusion and PDT | Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | 06/25 | 12/25 | | |
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA |
|
|
| Active, not recruiting | N/A | 554 | Canada, US | Cxbladder | Pacific Edge Limited | Hematuria, Urothelial Carcinoma | 12/24 | 12/24 | | |
| Kovacs, Michael J |
COBRRA, NCT03266783: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism |
|
|
| Recruiting | 4 | 2760 | Europe, Canada, RoW | Apixaban, Eliquis, Rivaroxaban, Xarelto | Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Institutes of Health Research (CIHR) | Venous Thromboembolism | 12/24 | 12/24 | | |
| Recruiting | N/A | 70 | Canada | Apixaban, Eliquis | Michael Kovacs, Ottawa Hospital Research Institute, Jewish General Hospital | Cancer Patients, Central Venous Catheter Thrombosis, Upper Extremity Thrombosis | 08/21 | 08/21 | | |
| Garg, Amit |
NCT00319579: Pilot Prospective Study: Long-term Health of Living Kidney Donors |
|
|
| Completed | N/A | 330 | Canada, US, RoW | | Amit Garg, Canadian Institutes of Health Research (CIHR) | Living Kidney Donors | 08/09 | 08/09 | | |
| Not yet recruiting | N/A | 4800 | Canada | Super High-Flux Dialyzer, expanded hemodialysis, Nipro ELISIO HX, High-Flux Dialyzer, conventional hemodialysis | Western University, Canada, Schulich School of Medicine and Dentistry, ICES, Population Health Research Institute, Nipro Canada Corporation, London Health Sciences Centre | Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD) | 01/30 | 01/30 | | |
NCT06270134: Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate |
|
|
| Not yet recruiting | N/A | 5000 | NA | Bicarbonate | McMaster University, Canadian Institutes of Health Research (CIHR) | Hemolysis, Renal Failure | 01/29 | 01/29 | | |
NCT04079582: Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag Canada) |
|
|
| Active, not recruiting | N/A | 25000 | Canada | Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L)., Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L). | Lawson Health Research Institute, ICES, Canadian Institutes of Health Research (CIHR) | Kidney Diseases, End-Stage Kidney Disease, Hemodialysis | 03/26 | 03/26 | | |
| Turkstra, Timothy P |
NCT03992092: Video Stylet vs. Flexible Bronchoscopy for C-Spine |
|
|
| Recruiting | N/A | 50 | Canada | C-MAC VS, Flexible Bronchoscopy | Lawson Health Research Institute | Intubation;Difficult, Intubation Complication | 12/24 | 12/24 | | |
| Jones, Philip M |
TRACTION, NCT04803747: A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery |
|
|
| Active, not recruiting | 4 | 8440 | Canada | Tranexamic acid (TXA), Placebo (0.9 % Saline) | University of Manitoba, Canadian Institutes of Health Research (CIHR), Health Sciences Centre Foundation, Manitoba, The Ottawa Hospital | Major Non-cardiac Surgeries | 03/24 | 10/24 | | |
CODEX, NCT04289142: Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients |
|
|
| Recruiting | 4 | 2400 | Canada | Dexmedetomidine Hydrochloride Group, Dexmedetomidine Hydrochloride | Sunnybrook Health Sciences Centre, London Health Sciences Centre, University Health Network, Toronto, McMaster University | Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders, Mental Disorders, Confusion, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Signs and Symptoms, Dexmedetomidine, Hypnotics and Sedatives, Central Nervous System Depressants, Physiological Effects of Drugs, Analgesics, Non-Narcotic, Analgesics, Molecular Mechanisms of Pharmacological Action | 03/26 | 03/26 | | |
| Recruiting | N/A | 65 | Canada | | Western University, Canada | Cesarean Section Complications, Attachment Disorder, Post Operative Recovery | 05/21 | 09/21 | | |
| Malthaner, Richard |
NCT03310125 / 2017-003836-35: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) |
|
|
| Completed | 3 | 3209 | Europe, Canada, US, RoW | Colchicine, Placebo | Population Health Research Institute, Hamilton Health Sciences Corporation | Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery | 07/23 | 07/23 | | |
| Recruiting | 3 | 272 | Europe, Canada, US, RoW | Lung Surgery, SR, Radiation therapy, SAbR | University of Texas Southwestern Medical Center | Non-Small Cell Lung Cancer | 12/28 | 12/28 | | |
| Completed | 2/3 | 29 | Canada | (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, ECF/ECX or FLOT, Carboplatin paclitaxel plus concurrent radiotherapy | Dr. Gordon Buduhan, CancerCare Manitoba, University of Toronto, London Health Sciences Centre | Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction | 08/23 | 08/23 | | |
NCT05314946: Nutritional Support During Induction Therapy for Esophageal Cancer |
|
|
| Recruiting | N/A | 26 | Canada | No feeding tube placed, Placement of a percutaneous feeding tube | Mehdi Qiabi | Esophageal Cancer, Nutrition Aspect of Cancer | 09/24 | 12/24 | | |
| Forbes, Thomas |
NCT05004051: ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA |
|
|
| Recruiting | N/A | 200 | Canada, US | ViTAA Analysis | ViTAA Medical Solutions | Abdominal Aortic Aneurysms | 12/26 | 12/26 | | |
| Silverman, Michael |
| Recruiting | 4 | 8000 | Europe, Canada, RoW | Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging | University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute | Staphylococcus Aureus Bacteremia | 12/28 | 12/28 | | |
| Active, not recruiting | 3 | 2900 | Canada | Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide | Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc. | COVID-19 | 03/24 | 05/24 | | |
| Recruiting | 3 | 471 | Europe, US, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma, CanFite BioPharma Ltd. | Hepatocellular Carcinoma, Cirrhosis | 02/25 | 10/25 | | |
NCT04247542: ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
|
|
| Completed | 2 | 53 | US | Ibezapolstat, ACX-362E, Vancomycin, Vancomycin oral | Acurx Pharmaceuticals Inc. | Clostridium Difficile Infection | 10/23 | 11/23 | | |
NCT04781387: Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection |
|
|
| Active, not recruiting | 2 | 108 | Canada, US | CRS3123, Active Comparator | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) | Clostridioides Difficile Infection | 02/24 | 04/24 | | |
| Recruiting | 2 | 20 | RoW | Namodenoson 25mg, CF102 | Can-Fite BioPharma | Pancreatic Adenocarcinoma, Pancreatic Cancer | 07/26 | 12/26 | | |
| Recruiting | 2 | 114 | Europe, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma, CanFite BioPharma Ltd. | NASH - Nonalcoholic Steatohepatitis | 04/25 | 10/25 | | |
NCT04544306: Partial Oral Antimicrobials to Treat Infective Endocarditis in People Who Inject Drugs |
|
|
| Recruiting | N/A | 50 | Canada | Partial oral antimicrobial therapy | Lawson Health Research Institute | Infective Endocarditis | 12/24 | 06/25 | | |
| Recruiting | N/A | 1800 | US | Therapeutic Hypothermia | University of Michigan, Johns Hopkins University, Medical University of South Carolina, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) | Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain | 07/28 | 08/28 | | |
| Mrkobrada, Marko |
| Recruiting | 4 | 2270 | Europe, Canada, RoW | Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban | Population Health Research Institute, Hamilton Health Sciences Corporation | Stroke, Atrial Fibrillation | 12/26 | 12/28 | | |
| Active, not recruiting | 3 | 1720 | Canada | Cytisine, Video Messaging | Population Health Research Institute | Smoking (Tobacco) Addiction, Smoking Cessation | 07/26 | 01/27 | | |
| Recruiting | N/A | 750 | Canada | Cardiac monitoring device | Population Health Research Institute | Atrial Fibrillation, Atrial Flutter | 08/26 | 12/26 | | |
| Weir, Matthew R |
NCT06474273: TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients |
|
|
| Not yet recruiting | 4 | 540 | Canada, RoW | Methylprednisolone, IV MP, Prednisone | University of Sydney, University of Manitoba | Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas | 12/29 | 12/29 | | |
| Active, not recruiting | 4 | 60 | Canada | Denosumab 60 mg/ml, Prolia, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate | Western University, Canada, ICES, Academic Medical Organization of Southwestern Ontario, Western University, The Kidney Foundation of Canada | Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Recruiting | 3 | 2750 | Europe, Canada, RoW | Spironolactone 25Mg Tablet, Placebo Oral Tablet | Population Health Research Institute, Canadian Institutes of Health Research (CIHR) | Endstage Renal Disease | 07/25 | 04/26 | | |
NCT04658017: GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection |
|
|
| Recruiting | N/A | 15 | US | GARNET device | Boa Biomedical, Inc., Avania | Bloodstream Infection | 10/21 | 12/21 | | |
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease |
|
|
| Recruiting | N/A | 3600 | Europe, Canada, RoW | Liberal phosphate target, Intensive phosphate target | The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago | Kidney Failure, Chronic, Hyperphosphatemia | 12/27 | 12/28 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
COPE-AKI, NCT05805709: A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the Trial |
|
|
| Recruiting | N/A | 2145 | US | Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education | University of Pittsburgh, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Acute Kidney Injury | 06/26 | 03/27 | | |
| Balogh, Zsolt |
EPO-TRAUMA, NCT04588311: ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients |
|
|
| Recruiting | 3 | 2500 | Europe, RoW | Epoetin Alfa 40000 UNT/ML, Eprex, Binocrit, Sodium Chloride 0.9%, Placebo, Saline | Australian and New Zealand Intensive Care Research Centre, University College Dublin, Medical Research Institute of New Zealand, Medical Research Future Fund, Health Research Board, Ireland, Health Research Council, New Zealand, Irish Critical Care Clinical Trials Network, ANZICS Clinical Trials Group, Monash University | Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries, Penetrating Injury, Blunt Injury, Major Trauma, Multiple Trauma | 12/25 | 12/25 | | |
NCT05146986: RibFix Blu Thoracic Fixation System Versus Non-surgical Treatment in Non-flail Chest Rib Fractures |
|
|
| Recruiting | N/A | 167 | RoW | Non surgical and Surgical | Zimmer Biomet | Rib; Fracture | 12/25 | 12/26 | | |
| Recruiting | N/A | 1100 | Europe, Canada, US, RoW | Accelerated medical clearance and surgery | Population Health Research Institute, Canadian Institutes of Health Research (CIHR), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Hip Fractures, Myocardial Injury | 02/27 | 05/27 | | |
NCT04112992: An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects |
|
|
| Recruiting | N/A | 600 | Europe, US, RoW | Any treatment that is used for a defect of any long bone | AO Innovation Translation Center | Limb Fracture, Bone Loss | 05/28 | 03/29 | | |
| Dhir, Shalini |
NCT03708302: Serratus and Parasternal Infrapectoral Block for Breast Surgery. |
|
|
| Recruiting | N/A | 120 | Canada | Unilateral serratus plane block, Unilateral parasternal infrapectoral block | Western University, Canada | Breast Pain, Post-Op Complication | 12/24 | 06/25 | | |
NCT05898581: PENG Block Vs. Intraoperative Local Anesthetic Infiltration for Total Hip Arthroplasty |
|
|
| Recruiting | N/A | 140 | Canada | PENG Block, Control Group | Lawson Health Research Institute | Anesthesia | 06/26 | 07/26 | | |
| Singh, Indu |
| Not yet recruiting | 1/2 | 100 | | | Griffith University, Griffith Health Institute and Gold Coast University Hospital (GHIGCUH) Collaborative Grant | Diabetes, Obesity, Cardiovascular | | | | |
ACTRN12612000674831: Role of Queen Garnet Plum in prevention of thrombotic (blood clotting) risk factors |
|
|
| Recruiting | N/A | 20 | | | Griffith University, Griffith University, Agri-Science Queensland, a service of the Department of Agriculture, Forestry and Fisheries (DAFF) | Oxidative stress induced metabolic syndrome, Thrombosis | | | | |
| Power, Adam |
LEADER-PAD, NCT04774159: Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk |
|
|
| Recruiting | 3 | 6150 | Canada | Colchicine 0.5 MG Oral Tablet, Colchicine, Colchicine-Placebo, Colchicine-Placebo tablet | Population Health Research Institute | Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation | 04/29 | 04/29 | | |
NCT06306716: A Clinical Study on New Negative Pressure Wound Therapy Dressing in the Management of Chronic & Acute Wounds |
|
|
| Recruiting | N/A | 23 | Canada | RENASYS Film with AIRLOCK Technology, RENASYS Dressing | Smith & Nephew, Inc. | Chronic Wounds, Acute Wounds | 09/25 | 09/25 | | |
| Dubois, Luc |
| Recruiting | N/A | 40 | Canada | Point of Care Ultrasound (POCUS), Usual Care | London Health Sciences Centre | Aortic Diseases | 10/21 | 12/21 | | |
| Louzada, Martha |
NCT06182774: Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 3 | 559 | Canada | Daratumumab, Lenalidomide, Dexamethasone | Canadian Cancer Trials Group, Canadian Institutes of Health Research (CIHR), Myeloma Canada | Multiple Myeloma | 01/32 | 07/32 | | |
| Active, not recruiting | 2/3 | 57 | Canada | Rivaroxaban, Xarelto, ASA, aspirin | Lawson Health Research Institute, The Ottawa Hospital, Dalhousie University, Niagara Health System, Hamilton Health Sciences Corporation | Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I, Multiple Myeloma With Failed Remission, Multiple Myeloma Stage III | 12/23 | 09/24 | | |
BOREALIS, NCT05272826: Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients |
|
|
| Recruiting | 2 | 75 | Canada | Iberdomide, CC-220, Bortezomib, Velcade, Dexamethasone, Decadron, Isatuximab, Sarclisa | Canadian Myeloma Research Group | Multiple Myeloma | 03/28 | 03/31 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
| Hoover, Douglas |
NCT03861507: Needle Localization During Prostate Brachytherapy Using Power Doppler Ultrasound |
|
|
| Recruiting | N/A | 20 | Canada | Prostate Brachytherapy | Western University, Canada | Prostate Cancer | 08/24 | 12/24 | | |
| Vogt, Kelly N |
CLEAN Wound, NCT04548661: Clinical Evaluation of Adults Undergoing Elective Surgery Utilizing Intraoperative Incisional Wound Irrigation |
|
|
| Recruiting | N/A | 2500 | Canada | Intraoperative incisional wound irrigation with povidone-iodine solution, Intraoperative incisional wound irrigation with saline | Sunnybrook Health Sciences Centre | Surgical Site Infection | 08/25 | 08/25 | | |
| McIntyre, Christopher W |
| Recruiting | 2 | 10 | Canada | Interdialytic peritoneal ultrafiltration with 10% dextrose solution | Lawson Health Research Institute, Sequana Medical N.V. | End Stage Renal Disease on Dialysis, Hemodialysis, Peritoneal Dialysis, Nonosmotic Sodium Storage | 11/24 | 12/24 | | |
NCT05185999: Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients |
|
|
| Completed | 1 | 10 | Canada | Icodextrin/Dextrose | Lawson Health Research Institute | Chronic Kidney Failure | 10/23 | 10/23 | | |
| Active, not recruiting | N/A | 18 | Canada | Reveal LINQ insertable cardiac monitoring system | Lawson Health Research Institute | Arrythmia, Cardiac, Sudden Cardiac Death, Hemodialysis | 09/24 | 12/24 | | |
NCT03640858: Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL |
|
|
| Completed | N/A | 82 | Canada | Theranova Dialyzer | London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's, Baxter Healthcare Corporation | End Stage Renal Disease | 04/23 | 04/23 | | |
| Recruiting | N/A | 20 | Canada | | Lawson Health Research Institute | Chronic Kidney Disease Requiring Chronic Dialysis, Interdialytic Weight Gain | 09/24 | 12/24 | | |
| Recruiting | N/A | 200 | Canada | Sodium-23 MRI | Lawson Health Research Institute | Chronic Kidney Disease, Nephrolithiasis, ADPKD | 12/24 | 12/24 | | |
| Recruiting | N/A | 37 | Canada | RespirAct | Lawson Health Research Institute, Heart and Stroke Foundation of Canada | Chronic Kidney Failure | 12/24 | 12/24 | | |
NCT03004547: Sodium Deposition in Soft Tissues of Patients With Kidney Disease |
|
|
| Recruiting | N/A | 400 | Canada | Measuring sodium content | Chris McIntyre | Haemodialysis Complication | 12/24 | 12/24 | | |
| Completed | N/A | 12 | Canada | Control group, SLEDD with a L-MOD | Lawson Health Research Institute | COVID-19, SARS | 12/23 | 03/24 | | |
| Recruiting | N/A | 50 | Canada | Furosemide Injection | Lawson Health Research Institute | Cardio-Renal Syndrome | 12/24 | 12/24 | | |
NCT04848636: Cardiac Tissue Sodium Assessment in CKD Patients Using Sodium MRI |
|
|
| Recruiting | N/A | 150 | Canada | Cardiac Sodium and Proton MRI | Lawson Health Research Institute | Chronic Kidney Diseases, Dialysis; Complications, Sodium Retention | 07/25 | 12/25 | | |
NCT06032208: An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL |
|
|
| Recruiting | N/A | 100 | Canada | Theranova Dialyzer | Lawson Health Research Institute, Baxter Healthcare Corporation | End Stage Renal Disease | 12/24 | 12/24 | | |
NCT06735378: Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury |
|
|
| Not yet recruiting | N/A | 30 | Canada | Intradialytic Cycling | London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's | Hemodialysis, Cardioprotection | 10/25 | 12/25 | | |
| Lawendy, Abdel |
NCT02212600: Determinants of Function and Clinically Important Outcomes in Proximal Humerus Fractures |
|
|
| Recruiting | N/A | 500 | Canada | Observational | London Health Sciences Centre, Unity Health Toronto | Humeral Fractures, Proximal | 12/23 | 12/23 | | |
NCT03439631: Patient Satisfaction With Tiered OR Versus Status Quo OR |
|
|
| Completed | N/A | 200 | Canada | Patient satisfaction questionnaire | Lawson Health Research Institute | Surgery | 11/23 | 11/23 | | |
| Recruiting | N/A | 1100 | Europe, Canada, US, RoW | Accelerated medical clearance and surgery | Population Health Research Institute, Canadian Institutes of Health Research (CIHR), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Hip Fractures, Myocardial Injury | 02/27 | 05/27 | | |
| Ball, Ian |
| Completed | 3 | 4800 | Europe, Canada, US, RoW | Placebo (0.9% saline), normal saline; NaCl 0.9%, Pantoprazole, Protonix | McMaster University, Canadian Institutes of Health Research (CIHR), Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, National Health and Medical Research Council, Australia | Gastrointestinal Hemorrhage (Clinically Important, Upper) | 10/23 | 01/24 | | |
| Recruiting | 2/3 | 1096 | Canada, RoW | higher chloride crystalloid, lower chloride crystalloid | McMaster University, The Physicians' Services Incorporated Foundation, Canadian Institutes of Health Research (CIHR) | Sepsis, Septic Shock | 11/25 | 03/26 | | |
| Not yet recruiting | N/A | 50 | NA | Therapeutic Normothermia Group | London Health Sciences Centre, Lawson Health Research Institute | Traumatic Brain Injury | 12/25 | 12/25 | | |
| Sebbag, Ilana |
NCT03592992: Spinal Hydromorphone Versus Morphine for Post-Cesarean Delivery Analgesia |
|
|
| Completed | 4 | 126 | Canada | Spinal Hydromorphone, Spinal Morphine | Lawson Health Research Institute | Postoperative Pain | 07/22 | 07/22 | | |
NCT04988893: Quality of Recovery Scores in Parturients With Obesity |
|
|
| Completed | N/A | 140 | Canada | | Lawson Health Research Institute | Quality of Recovery, Post Operative Pain | 03/23 | 03/23 | | |
| Recruiting | N/A | 65 | Canada | | Western University, Canada | Cesarean Section Complications, Attachment Disorder, Post Operative Recovery | 05/21 | 09/21 | | |
| Seidelin, Jakob |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Recruiting | 2 | 82 | Europe | Vedolizumab, Prednisolone, Infliximab | University of Copenhagen | Immune-Mediated Colitis | 04/25 | 04/25 | | |
SUCCES, NCT03942861: Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. |
|
|
| Recruiting | N/A | 50 | Europe | Solu-Medrol | Copenhagen University Hospital at Herlev | Ulcerative Colitis, Ultrasound Therapy; Complications | 09/21 | 02/22 | | |
| Corpuz, Roweena |
NCT05319028: Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Terminated | 2 | 2 | US | Mivavotinib, CB-659 | Calithera Biosciences, Inc | Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations | 02/23 | 02/23 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer |
|
|
| Recruiting | 4 | 78 | US | Fruquintinib, Fruzaqla™ | Takeda | Colorectal Cancer | 02/28 | 02/28 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
